Photo by finnnyc from unsplash
No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at… Click to show full abstract
No clear consensus exists for managing biochemically recurrent prostate cancer after prostatectomy. Interpretation of new data from the JCOG0401 trial warrants consideration of imaging techniques, prostate-specific antigen (PSA) levels at time of salvage radiotherapy (SRT), use of SRT ± salvage androgen deprivation therapy based on PSA levels, and the interval to biochemical failure.
Keywords:
salvage therapy;
salvage;
prostate cancer;
therapy biochemical
Journal Title: Nature Reviews Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Urology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!